Introduction
According to the GLOBOCAN database, approximately 573,000 new cases of bladder cancer were diagnosed worldwide in 2020, accounting for nearly 3% of all newly diagnosed cancer cases globally [2]. The highest incidence rates of bladder cancer among both men and women have been reported in Lebanon and certain regions of Southern Europe, whereas the lowest incidence rates have been observed in Central Africa, Western Africa, and Central America. These geographical variations are likely attributable to differences in exposure to environmental and occupational risk factors, tobacco consumption patterns, and levels of socioeconomic development. Accordingly, bladder cancer incidence has been shown to have a positive association with the Human Development Index and, to some extent, with gross domestic product per capita [7]. Based on GLOBOCAN estimates, bladder cancer ranks as the ninth most common cancer in Iran, with an age-standardized incidence rate (ASR) of 6.1 per 100,000 population. It is also the fifth most common malignancy among Iranian men, with an ASR of 10.1 per 100,000 population, and represents the tenth leading cause of cancer-related mortality in the country, with an age-standardized mortality rate (ASMR) of 2.1 per 100,000 population [2]. The highest age-standardized incidence rates have been reported in East Azerbaijan (17.6 per 100,000) and Kerman (15.8 per 100,000) provinces [2, 8]. In a study conducted in Mazandaran Province in 2012, the incidence rate of bladder cancer was estimated at 11.4 per 100,000 population [9]. Given the substantial geographical variability in bladder cancer incidence and the lack of comprehensive investigations assessing the incidence patterns and temporal trends of this malignancy in Mazandaran Province, existing epidemiological evidence regarding the burden of bladder cancer in this region remains limited. Therefore, the present study aimed to determine the incidence rate and evaluate the trends of bladder cancer among residents of Mazandaran Province during 2016–2020, using data obtained from the population-based cancer registry system.
Methods
The study population comprised all residents of Mazandaran Province who were diagnosed with primary malignant bladder cancer between 2016 and 2020. Eligible cases were identified using the International Classification of Diseases for Oncology (ICD-O) topography code C67 from the Population-Based Cancer Registry (PBCR) of Mazandaran University of Medical Sciences. Demographic and epidemiological information, including age at diagnosis, sex, county of residence, and place of residence (urban or rural), was extracted from the registry database. Data collection was performed according to the operational guidelines of the Iranian National Population-Based Cancer Registration Program [10]. Age-specific incidence rates were calculated by dividing the number of newly diagnosed bladder cancer cases in each age group by the corresponding population and expressing the results per 100,000 population using the direct standardization method. Descriptive statistics were used to summarize demographic and epidemiological characteristics. The Chi-square test was used to compare categorical variables, while the independent samples t-test was applied to compare the mean age between males and females and between urban and rural populations. All statistical analyses were performed using SPSS version 20, and P<0.05 was considered statistically significant.
Results and Discussion
A total of 1,370 patients with bladder cancer were registered in Mazandaran Province between 2016 and 2020. Histopathological confirmation was available for more than 83% of cases, indicating a high level of diagnostic reliability within the Population-Based Cancer Registry. The geographical distribution showed that most patients were diagnosed in Sari, Babol, and Amol counties, which are among the largest urban centers in the province and contain major referral hospitals.
The age-standardized incidence rate (ASR) of bladder cancer remained relatively stable throughout the study period, fluctuating between approximately 8 and 9 cases per 100,000 population without evidence of a marked increasing or decreasing trend. This finding is generally consistent with national cancer registry reports from Iran, although the incidence observed in Mazandaran was lower than that reported from several industrial provinces. Pourteymour et al. reported national ASRs of 8.50, 8.05, and 8.74 per 100,000 population during 2014–2016, indicating that the incidence in Mazandaran follows the overall national pattern despite regional differences [11].
Male patients accounted for 80.1% of all registered cases, whereas females represented only 19.9%, yielding a male-to-female ratio of approximately 4:1. This distribution closely resembles both national and international epidemiological patterns and reflects the greater exposure of men to established risk factors, such as cigarette smoking and occupational carcinogens. Similarly, a nationwide analysis of more than 51,000 bladder cancer cases in Iran reported that approximately 82% of patients were male, confirming that sex distribution in Mazandaran is comparable with the national profile [18].
The mean age of patients was 66.92 years, and the majority of cases occurred among individuals aged 60 years and older. No statistically significant differences were observed in mean age between men and women (P=0.215) or between urban and rural residents (P=0.255). These findings are in agreement with previous Iranian studies demonstrating that bladder cancer is predominantly a disease of older adults, with mean ages at diagnosis ranging from approximately 62 to 65 years [21]. The increasing incidence among elderly individuals is likely associated with cumulative exposure to carcinogenic agents, aging-related molecular alterations, and prolonged latency between exposure and tumor development.
Approximately two-thirds of patients resided in urban areas, while one-third lived in rural regions. Although residence was not associated with differences in age at diagnosis, the higher number of urban cases may reflect population density, greater accessibility to specialized diagnostic services, and more complete cancer registration in metropolitan areas. In conclusion, bladder cancer incidence in Mazandaran Province remained relatively stable between 2016 and 2020 and predominantly affected older men. The observed demographic pattern was consistent with national epidemiological evidence, while the provincial incidence remained lower than that reported from several high-risk regions of Iran.
Ethical Considerations
Compliance with ethical guidelines
This study was approved by the Research Ethics Committee of Imam Hospital affiliated with Mazandaran University of Medical Sciences (Code: IR.MAZUMS.IMAMHOSPITAL.REC.1402.099).
Funding
This study was funded by Mazandaran University of Medical Sciences.
Authors contributions
Conceptualization, methodology, and formal analysis: Reza Alizadeh-Navaei; writing the original draft: Reza Alizadeh-Navaei and Sahar Jafari; review & editing: Akbar Hedayatizadeh-Omran, Ehsan Zaboli, Mohammad Eslamijouybari, Maryam Alizadeh-Forutan, Mahmood Moosazadeh, and Dilyara Kaidarova. All authors read and approved the final version of the manuscript.
Conflicts of interest
All authors declared no conflicts of interest.
References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. [DOI:10.3322/caac.21492] [PMID]
- Wéber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024; 42(1):237. [DOI:10.1007/s00345-024-04949-8] [PMID]
- Mushtaq J, Thurairaja R, Nair R. Bladder cancer. Surgery (Oxford). 2019; 37(9):529-37. [DOI:10.1016/j.mpsur.2019.07.003]
- Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999; 12(1):97-111. [DOI:10.1128/CMR.12.1.97] [PMID]
- Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018; 8(1):1129. [DOI:10.1038/s41598-018-19199-z] [PMID]
- Al-Zalabani AH, Stewart KF, Wesselius A, Schols AM, Zeegers MP. Modifiable risk factors for the prevention of bladder cancer: A systematic review of meta-analyses. Eur J Epidemiol. 2016; 31(9):811-51. [DOI:10.1007/s10654-016-0138-6] [PMID]
- Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020; 8(1):15. [DOI:10.3390/medsci8010015] [PMID]
- Kalan Farmanfarma K, Mahdavifar N, Salehiniya H. Bladder cancer in Iran: An epidemiological review. Res Rep Urol. 2020; 12:91-103. [DOI:10.2147/RRU.S232417] [PMID]
- Akbarzadeh Pasha A, Mohammadi Kenari H, Hajian K, Alizade R. [The incidence of bladder cancer in Mazandaran province for three years (Persian)]. J Babol Univ Med Sci. 2012; 14(3):80-4.
- Ministry of Health and Medical Education. [Executive guidelines for the National Cancer Registration Program in Iran (Persian)]. Tehran: Ministry of Health and Medical Education; 2017. [Link]
- Partovipour E, Roshandel G, Motlagh A, Salavati F, Mohammadi G, Davanlou M, et al. Bladder Cancer Incidence in Iran: Results of the Iranian National Population-Based Cancer Registry from 2014 to 2016. Urol J. 2021; 19(4):274-80. [DOI:10.22037/uj.v18i.6760] [PMID]
- Hsiao BY, Su SY, Jhuang JR, Chiang CJ, Yang YW, Lee WC. Ensemble forecasting of a continuously decreasing trend in bladder cancer incidence in Taiwan. Sci Rep. 2021; 11(1):8373. [DOI:10.1038/s41598-021-87770-2] [PMID]
- Mahdavifar N, Ghoncheh M, Pakzad R, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of bladder cancer and their relationship with the development index in the world. Asian Pac J Cancer Prev. 2016; 17(1):381-6.[DOI:10.7314/APJCP.2016.17.1.381] [PMID]
- Lotfi F, Ravankhah Z, Rashidian H, Teimouri F, Maracy MR, Javanmard SH, et al. The Cancer Incidence Pattern in Isfahan Province: An Industrial Region in the Central Part of Iran. J Cancer Epidemiol. 2024; 2024:5592802.[DOI:10.1155/2024/5592802] [PMID]
- Nowroozi MR, Amini E, Farkhani EM, Nowroozi A, Ayati M, Momeni SA, et al. National and subnational incidence trend of bladder Cancer in Iran: Report of a 12-year period. Int J Cancer Manag. 2023; 16(1):e127005. [DOI:10.5812/ijcm-127005]
- Alkhodari M, Hadjileontiadis LJ, Jelinek HF, Khandoker AH. Heart Failure Assessment Using Multiparameter Polar Representations and Deep Learning. Annu Int Conf IEEE Eng Med Biol Soc. 2023; 2023:1-4. [DOI:10.1109/EMBC40787.2023.10341132]
- Zhu S, Zhao H. Sexual dimorphism in bladder cancer: A review of etiology, biology, diagnosis, and outcomes. Front Pharmacol. 2024; 14:1326627. [DOI:10.3389/fphar.2023.1326627] [PMID]
- Naserghandi A, Azizmohammad Looha M, Jameie M, Moradian Haft Cheshmeh Z, Namakin K, Golmakani N, et al. Incidence trends, histological subtypes, and topographical distribution of bladder cancer in Iran: A study based on the Iranian National Cancer Registry during 2006-2015. Front Oncol. 2024; 14:1423968. [DOI:10.3389/fonc.2024.1423968] [PMID]
- Gunlusoy B, Ceylan Y, Degirmenci T, Aydogdu O, Bozkurt IH, Yonguc T, et al. The potential effect of age on the natural behavior of bladder cancer: Does urothelial cell carcinoma progress differently in various age groups? Kaohsiung J Med Sci. 2016; 32(5):261-6. [DOI:10.1016/j.kjms.2016.03.002] [PMID]
- Telli O, Sarici H, Ozgur BC, Doluoglu OG, Sunay MM, Bozkurt S, et al. Urothelial cancer of bladder in young versus older adults: Clinical and pathological characteristics and outcomes. Kaohsiung J Med Sci. 2014; 30(9):466-70. [DOI:10.1016/j.kjms.2014.02.017] [PMID]
- Salehi A, Khezri AA, Malekmakan L, Aminsharifi A. Epidemiologic status of bladder cancer in Shiraz, southern Iran. Asian Pac J Cancer Prev. 2011; 12(5):1323-7. [PMID]